Results 31 to 40 of about 244,949 (162)

Anti-Vascular Endothelial Growth Factor Antibody Suppresses ERK and NF-κB Activation in Ischemia-Reperfusion Lung Injury. [PDF]

PLoS ONE, 2016
Ischemia-reperfusion (IR)-induced acute lung injury (ALI) is implicated in several clinical conditions like lung transplantation, acute pulmonary embolism after thrombolytic therapy, re-expansion of collapsed lung from pneumothorax or pleural effusion ...
Chou-Chin Lan, Chung-Kan Peng, Shih-En Tang, Shu-Yu Wu, Kun-Lun Huang, Chin-Pyng Wu   +5 more
doaj   +1 more source

Anti-VEGF Therapy in Myopic CNV

Current Drug Targets, 2021
In this narrative-review, we report the most recent data from the literature of anti-vascular endothelial growth factor treatment for myopic choroidal neovascularization (mCNV). Myopic CNV is the most frequent sight-threatening complication of pathologic myopia.
Lisa Toto, Luca Di Antonio, Olivia Costantino, Rodolfo Mastropasqua   +3 more
openaire   +2 more sources

Tuberculosis pathophysiology and anti-VEGF intervention

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022
The pathophysiological understanding of tuberculosis is growing, and with this growth comes the possibility of applying established pharmaceuticals in new ways. These new ways interlude with the many mechanisms by which the intracellular pathogen, Mycobacterium tuberculosis, thrives in its human host.
openaire   +3 more sources

Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis [PDF]

International Journal of Ophthalmology, 2017
AIM: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) combined with photodynamic therapy (PDT) versus anti-VEGF monotherapy for polypoidal choroidal vasculopathy (PCV).
Long-Hui Han1, Li-Fei Yuan1, Xu Liang2, Xin Jia1, Ming-Lian Zhang1   +4 more
doaj   +1 more source

Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry

Scientific Reports
To compare baseline characteristics, initial response and 12-month efficacy and safety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexamethasone implants (DEX) or anti-vascular endothelial growth factor ...
Gonzaga Garay-Aramburu, Adrian Hunt, Carolina Arruabarrena, Hemal Mehta, Alessandro Invernizzi, Pierre-Henry Gabrielle, Tremeur Guillaumie, Benjamin Wolff, Mark C. Gillies, Javier Zarranz-Ventura   +9 more
doaj   +1 more source

Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models

Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors show limited efficacy against immune-desert tumors, including ovarian cancer. We investigated triple therapy combining anti-programmed cell death-ligand 1 (PD-L1) antibody, anti-vascular endothelial growth factor ...
Akihiko Ueda, Ryusuke Murakami, Kentaro Ishida, Kohei Hamada, Jumpei Ogura, Shunsuke Kawahara, Yuka Mise, Yuko Hosoe, Masamichi Sugimoto, Daiko Wakita, Taito Miyamoto, Rin Mizuno, Mana Taki, Koji Yamanoi, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai   +16 more
doaj   +1 more source

A study of the relationship between cytokine levels and the response to anti-VEGF therapy in polypoid choroidal vasculopathy with different choroidal thicknesses

Frontiers in Endocrinology
PurposePolypoidal choroidal vasculopathy (PCV) is an irreversible retinal choroidal disease. Individuals with PCV exhibit diverse baseline characteristics, including systemic characteristics, ocular traits, metabolic factor levels, and different ...
Su Dong, Pan Fan, Haotian Yu, Bo Jiang, Dawei Sun   +4 more
doaj   +1 more source

Glaucoma Drainage Device Erosions in Patients Receiving Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy

Clinical Ophthalmology, 2022
Yasmin Florence Khodeja Islam, Elizabeth A Vanner, Arindel SR Maharaj, Stephen G Schwartz, Krishna Kishor Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Krishna ...
Islam YFK, Vanner EA, Maharaj ASR, Schwartz SG, Kishor K   +4 more
doaj  

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Scientific Reports, 2023
To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included
Sheng-Chu Chi, Yi-No Kang, Yi-Ming Huang
doaj   +1 more source

Human Platelets Take up Anti-VEGF Agents

Journal of Ophthalmology, 2021
Purpose. Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal application.
B. Sobolewska, B. Fehrenbacher, P. Münzer, H. Kalbacher, S. Geue, Konstantinos Stellos, M. Schaller, F. Ziemssen   +7 more
doaj   +1 more source